**Temad Pharmaceutical Raw Material Production Company**, with a total sales of 1,446 billion Toman over the first 7 months and 220 billion Toman in Mehr 1403, has recorded a 51% growth compared to the same 7-month period in 1402 and a 64% increase compared to last year’s Mehr.
Dr. Yahya Mirzaei, CEO of Temad, stated: “Despite the liquidity challenges facing the entire pharmaceutical industry, which indeed can create disruptions in the supply chain, thanks to the grace of Almighty God and the efforts of our dedicated team, we have maintained an upward trend in our key performance indicators at Temad.”
“The prolonged collection period has created issues in timely procurement of raw materials, which subsequently disrupts production and other sections. Temad is no exception to this rule, and we are indeed experiencing severe liquidity constraints.”
“I hope that with increased cash flow to companies, accelerated and facilitated loan conditions from the country’s pharmaceutical industry policymakers, and more attention from both partner companies within the Tamin Pharmaceutical Group and external companies towards the payment of debts to raw material manufacturers — who are on the front line of the supply chain — we can prevent production stoppages.”
